115 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
51 | 31101118 | Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase. | 2019 May 17 | 1 |
52 | 31296812 | [Hereditary Breast and Ovarian Cancer Syndrome]. | 2019 Jul | 1 |
53 | 28146604 | The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury. | 2018 Jan | 1 |
54 | 29382645 | First PARP Inhibitor Ok'd for Breast Cancer. | 2018 Mar | 1 |
55 | 29465803 | Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells. | 2018 Apr | 1 |
56 | 29582690 | Olaparib for the treatment of breast cancer. | 2018 Jun | 1 |
57 | 29748182 | A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. | 2018 Sep 1 | 1 |
58 | 29898896 | Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease. | 2018 Sep | 1 |
59 | 29983873 | Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells. | 2018 Jun 19 | 2 |
60 | 30057890 | Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status. | 2018 | 1 |
61 | 30084837 | Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. | 2018 Oct 15 | 1 |
62 | 30232143 | Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response. | 2018 Dec | 1 |
63 | 30333000 | Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. | 2018 Oct 17 | 1 |
64 | 30353044 | Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. | 2018 Nov | 1 |
65 | 30555227 | Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. | 2018 | 1 |
66 | 28138868 | Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer. | 2017 Mar | 1 |
67 | 28323658 | Changing face of metastatic prostate cancer: the law of diminishing returns holds true. | 2017 May | 1 |
68 | 28395540 | Olaparib for the treatment of breast cancer. | 2017 Jun | 1 |
69 | 28450425 | Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. | 2017 Sep | 1 |
70 | 28450426 | Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. | 2017 Sep | 1 |
71 | 28454085 | Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. | 2017 Jul 18 | 2 |
72 | 28512243 | Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response. | 2017 Jun 15 | 1 |
73 | 28916476 | Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis. | 2017 Dec | 1 |
74 | 29290761 | The OlympiAD trial: who won the gold? | 2017 | 1 |
75 | 26899229 | Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. | 2016 | 1 |
76 | 26909613 | Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. | 2016 Mar 15 | 2 |
77 | 26934368 | Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells. | 2016 Mar | 1 |
78 | 26961146 | Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. | 2016 Jun | 1 |
79 | 26961668 | Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer. | 2016 | 1 |
80 | 27065456 | Homologous recombination deficiency and ovarian cancer. | 2016 Jun | 1 |
81 | 27345073 | The integration of BRCA testing into oncology clinics. | 2016 Jun 23 | 1 |
82 | 27617661 | Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. | 2016 Nov | 1 |
83 | 27708239 | FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. | 2016 Nov 15 | 1 |
84 | 27924011 | Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction. | 2016 Dec 15 | 1 |
85 | 25404465 | PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice. | 2015 Feb | 1 |
86 | 25583815 | Olaparib effective in four advanced cancers. | 2015 Jan | 1 |
87 | 25634209 | Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage. | 2015 Apr 1 | 1 |
88 | 25758301 | [Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: a review]. | 2015 Mar | 1 |
89 | 25975349 | The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. | 2015 Jul | 6 |
90 | 25981132 | Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. | 2015 Sep | 2 |
91 | 26095524 | XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. | 2015 Jun 22 | 1 |
92 | 26097887 | A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells. | 2015 | 2 |
93 | 26303225 | PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. | 2015 Oct | 1 |
94 | 26310895 | Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics. | 2015 Sep 18 | 1 |
95 | 26312527 | Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation. | 2015 | 1 |
96 | 26510020 | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. | 2015 Oct 29 | 2 |
97 | 24534203 | Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. | 2014 Jun 28 | 1 |
98 | 24632590 | Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. | 2014 May 30 | 1 |
99 | 24748377 | Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer. | 2014 | 1 |
100 | 24784564 | Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. | 2014 May 15 | 1 |